Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies

American Journal of Clinical Pathology

Volumn 130, Issue 5, 2008, Pages 702-711

  Davern, Sandra ^a   Tang, Lian X ^a   Williams, Teresa K ^a   Macy, Sallie D ^a   Wall, Jonathan S ^a   Weiss, Deborah T ^a   Solomon, Alan ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloidosis; Free light chains; Immunoassay; Immunoglobulins; Multiple myeloma

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; BENCE JONES PROTEIN; DIAGNOSTIC AGENT; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TURBIDIMETRY; ADULT; AGED; ANIMAL; COMPARATIVE STUDY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MOUSE; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AMYLOIDOSIS; ANIMALS; ANTIBODIES, MONOCLONAL; BENCE JONES PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; MULTIPLE MYELOMA; WALDENSTROM MACROGLOBULINEMIA;

EID: 55249100513     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPNS6K1CYJPDBA     Document Type: Article

References (36)

1. Solomon A. Monoclonal immunoglobulins as biomarkers of cancer. In: Sell S, ed. Cancer Markers: Developmental and Diagnostic Significance. Clifton, NJ: Humana Press; 1980:57-87.
2. Solomon A, Weiss DT, Herrera GA. Renal diseases associated with multiple myeloma and related plasma cell dyscrasias. In: Berenson JR, ed. Biology and Management of Multiple Myeloma. Totowa, NJ: Humana Press; 2004:281-302.
3. κ epitopes not available on whole immunoglobulins. Clin Exp Immunol. 1983;52:234-240.
4. Axiak SM, Krishnamoorthy L, Guinan J, et al. Quantitation of free kappa light chains in serum and urine using a monoclonal antibody based inhibition enzyme-linked immunoassay. J Immunol Methods. 1987;99:141-147.
5. Nelson M, Brown RD, Gibson J, et al. Measurement of free kappa and lambda chains in serum and the significance of their ratio in patients with multiple myeloma. Br J Haematol. 1992;81:223-230.
6. Nakano T, Nagata A. ELISAs for free light chains of human immunoglobulins using monoclonal antibodies: comparison of their specificity with available polyclonal antibodies. J Immunol Methods. 2003;275:9-17.
7. Nakano T, Miyazaki S, Takahashi H, et al. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin Chem Lab Med. 2006;44:522-532.
8. Abe M, Goto T, Kennel SJ, et al. Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies. Am J Clin Pathol. 1993;100:67-74.
9. Abe M, Goto T, Kosaka M, et al. Differences in kappa to lambda (κ:λ) ratios of serum and urinary free light chains. Clin Exp Immunol. 1998;111:457-462.
10. Solomon A. Light chains of human immunoglobulins. Methods Enzymol. 1985;116:101-121.
11. Murphy CL, Eulitz M, Hrncic R, et al. Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol. 2001;116:135-142.
12. Murphy CL, Wang S, Williams T, et al. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol. 2006;412:48-62.
13. Fleischman JB, Pain RH, Porter RR. Reduction of gamma-globulins. Arch Biochem Biophys. 1962;(suppl 1):174-180.
14. Solomon A, Weiss DT, Macy SD, et al. Immunocytochemical detection of kappa and lambda light chain V region subgroups in human B-cell malignancies. Am J Pathol. 1990;137:855-862.
15. Solomon A, McLaughlin CL. Bence-Jones proteins and light chains of immunoglobulins, I: formations and characterization of amino-terminal (variant) and carboxyl-terminal (constant) halves. J Biol Chem. 1969;244:3393-3404.
16. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;8:32-59.
17. Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97:2900-2902.
18. Lachman HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78-84.
19. Abraham RS, Katzmann JA, Clark RJ, et al. Quantitative analyses of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol. 2003;119:274-278.
20. Rajkumar SV, Kyle RA, Therneau TM, et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol. 2004;127:308-310.
21. Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol. 2004;126:348-354.
22. Tate J, Mollee P, Gill D. Serum free light chains for monitoring multiple myeloma [letter]. Br J Haematol. 2005;128:405-406.
23. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107:3854-3858.
24. van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827-832.
25. Morris KL, Tate JR, Gill D, et al. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Intern Med. 2007;37:456-463.
26. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785-789.
27. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol. 2008;141:413-422.
28. McLaughlin CL, Solomon A. A hidden antigenic site localized to the constant region of light chains of immunoglobulins. Science. 1973;179:580-582.
29. Solomon A. Bence Jones proteins and light chains of immunoglobulins, XIV: conformational dependency and molecular localization of the kappa (κ) and lambda (λ) antigenic determinants. Scand J Immunol. 1976;5:685-695.
30. Solomon A, McLaughlin CL, Steinberg AG. Bence Jones proteins and light chains of immunoglobulins, III: inv antigenicity: a genetic expression with serologic dependency on the intact kappa light chain molecule. Immunochemistry. 1970;7:709-713.
31. Coriu D, Weaver K, Schell M, et al. A molecular basis for nonsecretory myeloma. Blood. 2004;104:829-831.
32. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47:673-680.
33. Katzman JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free and free immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437-1444.
34. Tate JR, Gill D, Cobcroft R, et al. Practical considerations for the measurement of free light chains in serum. Clin Chem. 2003;49:1957-1958.
35. Daval S, Tridon A, Mazeron N, et al. Risk of antigen excess in serum free light chain measurements [letter]. Clin Chem. 2007;53:1985-1986.
36. Tate JR, Mollee M, Dimeski G, et al. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta. 2007;376:30-36.